Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

doi:10.1038/s41588-018-0200-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Nature genetics - 1 Sept 2018

Miao Diana, Margolis Claire A, Vokes Natalie I, Liu David, Taylor-Weiner Amaro, Wankowicz Stephanie M, Adeegbe Dennis, Keliher Daniel, Schilling Bastian, Tracy Adam, Manos Michael, Chau Nicole G, Hanna Glenn J, Polak Paz, Rodig Scott J, Signoretti Sabina, Sholl Lynette M, Engelman Jeffrey A, Getz Gad, Jänne Pasi A, Haddad Robert I, Choueiri Toni K, Barbie David A, Haq Rizwan, Awad Mark M, Schadendorf Dirk, Hodi F Stephen, Bellmunt Joaquim, Wong Kwok-Kin, Hammerman Peter, Van Allen Eliezer M

Abstract excerpt

Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we uniformly analyzed whole-exome sequencing (WES) of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy, including radiographic response, across...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Exome

Share to Genomics

Share to Immunity

Share to Microsatellite Repeats

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 30150660
DOI: 10.1038/s41588-018-0200-2
PMCID: PMC6119118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.PMID 30150660Read ↗

Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.Semantic proximity Read ↗

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerSemantic proximity Read ↗

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read ↗

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.Semantic proximity Read ↗

A molecular portrait of microsatellite instability across multiple cancersSemantic proximity Read ↗

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Semantic proximity Read ↗

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.Semantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated TumorsSemantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.